Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer

Breast Cancer Research

Volumn 11, Issue 5, 2009, Pages

  Wicha, Max S ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TRANSCRIPTION FACTOR EZH2; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; EZH2 PROTEIN, MOUSE; HISTONE LYSINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TRANSCRIPTION FACTOR;

BREAST CANCER; BREAST DEVELOPMENT; BREAST TUMOR; CANCER STEM CELL; DRUG EFFICACY; EDITORIAL; GENE FUNCTION; HUMAN; NONHUMAN; PROTEIN FUNCTION; TUMOR CELL; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; MOUSE; NOTE; DNA REPAIR; DOWN REGULATION; EZH2 GENE; GENE OVEREXPRESSION; GENE TARGETING; GERMLINE MUTATION; PROTEIN EXPRESSION;

ANIMALS; BRCA1 PROTEIN; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; POLY(ADP-RIBOSE) POLYMERASES; TRANSCRIPTION FACTORS;

EID: 77449113489     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2362     Document Type: Editorial

References (14)

1. Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, Nederlof P, Yu Q, Jonkers J, van Lohuizen M, Pietersen AM. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to polycomb repressive complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 2009, 11:R63. 10.1186/bcr2354, 19709408, 2750125.
2. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
3. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.
4. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. 10.1038/nature03443, 15829966.
5. Tonini T, D'Andrilli G, Fucito A, Gaspa L, Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 2008, 214:295-300. 10.1002/jcp.21241, 17786943.
6. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003, 100:11606-11611. 208805, 14500907, 10.1073/pnas.1933744100.
7. Arnes JB, Collett K, Akslen LA. Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology 2008, 52:370-380. 10.1111/j.1365-2559.2007.02957.x, 18269588.
8. Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G, Tarakhovsky A, Fuchs E. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 2009, 136:1122-1135. 2716120, 19303854, 10.1016/j.cell.2008.12.043.
9. Pietersen AM, Horlings HM, Hauptmann M, Langerød A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, Vijver MJ, van Lohuizen M. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 2008, 10:R109. 19099573, 10.1186/bcr2214, 2656906.
10. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008, 105:1680-1685. 2234204, 18230721, 10.1073/pnas.0711613105.
11. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913. 10.1038/nm.2000, 19648928.
12. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009, 28:843-853. 2643353, 19079346, 10.1038/onc.2008.433.
13. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008, 26:2813-2820. 10.1200/JCO.2008.16.3931, 18539959.
14. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819. 10.1038/nrc1457, 15510162.